Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and rheumatology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative, for the treatment of chronic and acute constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol injection for treating euvolemic and hypervolemic hyponatremia; and Vibativ injection, for the treatment of certain serious bacterial infections. It also develops RediTrex injection for the treatment of active rheumatoid, juvenile idiopathic, and severe psoriatic arthritis, as well as disabling psoriasis. The company markets and sells its products through sales representatives and district managers. In addition, the company is developing ifetroban, a product candidate that is in phase II clinical trial for the treatment of aspirin-exacerbated respiratory disease, systemic sclerosis, and duchenne muscular dystrophy; and has completed phase II clinical trial for the treatment of hepatorenal syndrome and portal hypertension. Cumberland Pharmaceuticals Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee.
IPO Year: 2009
Exchange: NASDAQ
Website: cumberlandpharma.com
| Date | Price Target | Rating | Analyst |
|---|
4 - CUMBERLAND PHARMACEUTICALS INC (0001087294) (Issuer)
4 - CUMBERLAND PHARMACEUTICALS INC (0001087294) (Issuer)
4 - CUMBERLAND PHARMACEUTICALS INC (0001087294) (Issuer)
4 - CUMBERLAND PHARMACEUTICALS INC (0001087294) (Issuer)
4 - CUMBERLAND PHARMACEUTICALS INC (0001087294) (Issuer)
4 - CUMBERLAND PHARMACEUTICALS INC (0001087294) (Issuer)
4 - CUMBERLAND PHARMACEUTICALS INC (0001087294) (Issuer)
4 - CUMBERLAND PHARMACEUTICALS INC (0001087294) (Issuer)
4 - CUMBERLAND PHARMACEUTICALS INC (0001087294) (Issuer)
4 - CUMBERLAND PHARMACEUTICALS INC (0001087294) (Issuer)
Analysis Shows 23% Reduction in Morphine Use with Favorable Safety Profile in Patients 60 Years of Age and Older NASHVILLE, Tenn., May 27, 2025 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a specialty pharmaceutical company, today announced the publication of its study investigating Caldolor® (intravenous ibuprofen) in older patients. The analysis evaluated the safety and efficacy of Caldolor for the management of pain and fever in patients 60 years of age and older. It marks an important advancement in pain management for older individuals, as it's one of the first studies specifically evaluating Caldolor in this vulnerable population.
NASHVILLE, Tenn., May 6, 2025 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a specialty pharmaceutical company, announced today that its product portfolio of FDA-approved brands delivered combined net revenues of $11.7 million during the first quarter of 2025, a 38% increase over the prior year period. As a result the Company generated a net profit of $1.3 million for the quarter, adjusted earnings of $2.4 million, and cash flow from operations of $3.9 million. Cumberland ended the quarter with approximately $70 million in total assets, $41.6 million in liabil
NASHVILLE, Tenn., April 29, 2025 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a specialty pharmaceutical company, announced today that it will release its first quarter 2025 financial results and provide a Company update after the market closes on Tuesday, May 6, 2025. A conference call will be held on May 6 at 4:30 p.m. Eastern Time to discuss the results and update. The link to register is: https://register-conf.media-server.com/register/BIea2bc7f82dd24caea135dbe5460d9b6f. Once registered, participants can dial in from their phone using a dial-in and PIN nu
Ifetroban demonstrated significant 5.4% improvement in cardiac function NASHVILLE, Tenn., March 19, 2025 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a specialty pharmaceutical company with development efforts focused on rare diseases, today announced that results from its Phase 2 FIGHT DMD clinical trial were selected for a late-breaking presentation at the Muscular Dystrophy Association (MDA) Clinical & Scientific Conference in Dallas. The trial demonstrated significant cardiac benefits for patients with Duchenne muscular dystrophy (DMD), potentially addressing the leading cause of death in this devastating disease.
2024 highlights include expanded product labeling, key FDA designations and new study publications Recent developments include Phase 2 DMD Study Breakthrough Results and Vibativ China approval NASHVILLE, Tenn., March 4, 2025 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a specialty pharmaceutical company, announced today that its product portfolio of FDA-approved brands delivered combined net revenues of $10.4 million during the fourth quarter of 2024, an 11.6% increase over the prior year period. Net revenues for the full year 2024 were $38 million. Cumberla
NASHVILLE, Tenn., Feb. 25, 2025 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a specialty pharmaceutical company, announced today that it will release its annual 2024 financial results and provide a company update after the market closes on Tuesday, March 4, 2025. A conference call will be held on March 4 at 4:30 p.m. Eastern Time to discuss the results. To participate in the call, please register at https://register.vevent.com/register/BIafb49dfab9014db59440ff63e1d827b2. Once registered, participants can dial in from their phone using a dial-in and PIN number
Vibativ® is a life-saving antibiotic for pneumonia and serious skin infections Approval in China paves the way for launch in world's second-largest market NASHVILLE, Tenn. and SHANGHAI, Feb. 18, 2025 /PRNewswire/ -- Specialty pharmaceutical companies Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) and SciClone Pharmaceuticals (Holdings) Limited ("SciClone Pharmaceuticals" or "SciClone") today announced the NMPA (National Medical Products Administration) approval of Cumberland's Vibativ® (telavancin) injection in China. The announcement follows an agreement between the companies providing SciClone the exclusive rights to register, promote and distribute the product to patients in that country.
NASHVILLE, Tenn., Feb. 4, 2025 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a specialty pharmaceutical company with development efforts focused on new products for rare diseases, today announced positive top-line results from its Phase 2 FIGHT DMD trial. The study evaluated ifetroban, a novel oral therapy for Duchenne muscular dystrophy (DMD) heart disease – the leading cause of death in DMD patients. It marks a breakthrough for these patients, as it's the first successful Phase 2 study specifically targeting the cardiac complications of their condition. DMD
- New Dosing Regimen Simplifies Administration - NASHVILLE, Tenn., Dec. 9, 2024 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a specialty pharmaceutical company focused on delivering high-quality products to improve patient care, announced today the FDA has approved a supplemental New Drug Application (sNDA) for its Acetadote® (N-acetylcysteine for injection) product. Acetadote is an intravenous (IV) formulation of N-acetylcysteine (NAC) indicated to prevent or lessen liver injury after ingestion of potentially toxic quantities of acetaminophen1. Acetaminoph
– New Real World Study of 150,000 Patients Favors Caldolor over ketorolac – – DMD Program Receives FDA Orphan Drug & Rare Pediatric Disease Designations – NASHVILLE, Tenn., Nov. 7, 2024 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a specialty pharmaceutical company, today announced that its portfolio of FDA-approved brands delivered combined revenues of $9.1 million during the third quarter of 2024. The company ended the third quarter of 2024 with $77 million in total assets, $52 million in liabilities and $25 million of shareholders' equity.
4 - CUMBERLAND PHARMACEUTICALS INC (0001087294) (Issuer)
4 - CUMBERLAND PHARMACEUTICALS INC (0001087294) (Issuer)
4 - CUMBERLAND PHARMACEUTICALS INC (0001087294) (Issuer)
4 - CUMBERLAND PHARMACEUTICALS INC (0001087294) (Issuer)
4 - CUMBERLAND PHARMACEUTICALS INC (0001087294) (Issuer)
4 - CUMBERLAND PHARMACEUTICALS INC (0001087294) (Issuer)
4 - CUMBERLAND PHARMACEUTICALS INC (0001087294) (Issuer)
4 - CUMBERLAND PHARMACEUTICALS INC (0001087294) (Issuer)
4 - CUMBERLAND PHARMACEUTICALS INC (0001087294) (Issuer)
4 - CUMBERLAND PHARMACEUTICALS INC (0001087294) (Issuer)
NASHVILLE, Tenn., July 19, 2022 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a specialty pharmaceutical company, announced today that Martin Brown Jr. has joined the company's Board of Directors. Brown previously served for 10 years on the Board of directors of Brown-Forman Corporation, a large American wine and spirits company listed on the New York Stock Exchange. The brands in Brown-Forman's portfolio include Jack Daniel's and Woodford Reserve whiskeys, Benriach scotch, Herradura tequila and Finlandia vodka. Brown is an attorney at Adams and Reese LLP, a
10-Q - CUMBERLAND PHARMACEUTICALS INC (0001087294) (Filer)
8-K - CUMBERLAND PHARMACEUTICALS INC (0001087294) (Filer)
8-K - CUMBERLAND PHARMACEUTICALS INC (0001087294) (Filer)
8-K - CUMBERLAND PHARMACEUTICALS INC (0001087294) (Filer)
DEFA14A - CUMBERLAND PHARMACEUTICALS INC (0001087294) (Filer)
DEF 14A - CUMBERLAND PHARMACEUTICALS INC (0001087294) (Filer)
10-K - CUMBERLAND PHARMACEUTICALS INC (0001087294) (Filer)
8-K - CUMBERLAND PHARMACEUTICALS INC (0001087294) (Filer)
8-K - CUMBERLAND PHARMACEUTICALS INC (0001087294) (Filer)
424B5 - CUMBERLAND PHARMACEUTICALS INC (0001087294) (Filer)
Analysis Shows 23% Reduction in Morphine Use with Favorable Safety Profile in Patients 60 Years of Age and Older NASHVILLE, Tenn., May 27, 2025 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a specialty pharmaceutical company, today announced the publication of its study investigating Caldolor® (intravenous ibuprofen) in older patients. The analysis evaluated the safety and efficacy of Caldolor for the management of pain and fever in patients 60 years of age and older. It marks an important advancement in pain management for older individuals, as it's one of the first studies specifically evaluating Caldolor in this vulnerable population.
NASHVILLE, Tenn., May 6, 2025 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a specialty pharmaceutical company, announced today that its product portfolio of FDA-approved brands delivered combined net revenues of $11.7 million during the first quarter of 2025, a 38% increase over the prior year period. As a result the Company generated a net profit of $1.3 million for the quarter, adjusted earnings of $2.4 million, and cash flow from operations of $3.9 million. Cumberland ended the quarter with approximately $70 million in total assets, $41.6 million in liabil
NASHVILLE, Tenn., April 29, 2025 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a specialty pharmaceutical company, announced today that it will release its first quarter 2025 financial results and provide a Company update after the market closes on Tuesday, May 6, 2025. A conference call will be held on May 6 at 4:30 p.m. Eastern Time to discuss the results and update. The link to register is: https://register-conf.media-server.com/register/BIea2bc7f82dd24caea135dbe5460d9b6f. Once registered, participants can dial in from their phone using a dial-in and PIN nu
Ifetroban demonstrated significant 5.4% improvement in cardiac function NASHVILLE, Tenn., March 19, 2025 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a specialty pharmaceutical company with development efforts focused on rare diseases, today announced that results from its Phase 2 FIGHT DMD clinical trial were selected for a late-breaking presentation at the Muscular Dystrophy Association (MDA) Clinical & Scientific Conference in Dallas. The trial demonstrated significant cardiac benefits for patients with Duchenne muscular dystrophy (DMD), potentially addressing the leading cause of death in this devastating disease.
2024 highlights include expanded product labeling, key FDA designations and new study publications Recent developments include Phase 2 DMD Study Breakthrough Results and Vibativ China approval NASHVILLE, Tenn., March 4, 2025 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a specialty pharmaceutical company, announced today that its product portfolio of FDA-approved brands delivered combined net revenues of $10.4 million during the fourth quarter of 2024, an 11.6% increase over the prior year period. Net revenues for the full year 2024 were $38 million. Cumberla
NASHVILLE, Tenn., Feb. 25, 2025 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a specialty pharmaceutical company, announced today that it will release its annual 2024 financial results and provide a company update after the market closes on Tuesday, March 4, 2025. A conference call will be held on March 4 at 4:30 p.m. Eastern Time to discuss the results. To participate in the call, please register at https://register.vevent.com/register/BIafb49dfab9014db59440ff63e1d827b2. Once registered, participants can dial in from their phone using a dial-in and PIN number
Vibativ® is a life-saving antibiotic for pneumonia and serious skin infections Approval in China paves the way for launch in world's second-largest market NASHVILLE, Tenn. and SHANGHAI, Feb. 18, 2025 /PRNewswire/ -- Specialty pharmaceutical companies Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) and SciClone Pharmaceuticals (Holdings) Limited ("SciClone Pharmaceuticals" or "SciClone") today announced the NMPA (National Medical Products Administration) approval of Cumberland's Vibativ® (telavancin) injection in China. The announcement follows an agreement between the companies providing SciClone the exclusive rights to register, promote and distribute the product to patients in that country.
NASHVILLE, Tenn., Feb. 4, 2025 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a specialty pharmaceutical company with development efforts focused on new products for rare diseases, today announced positive top-line results from its Phase 2 FIGHT DMD trial. The study evaluated ifetroban, a novel oral therapy for Duchenne muscular dystrophy (DMD) heart disease – the leading cause of death in DMD patients. It marks a breakthrough for these patients, as it's the first successful Phase 2 study specifically targeting the cardiac complications of their condition. DMD
- New Dosing Regimen Simplifies Administration - NASHVILLE, Tenn., Dec. 9, 2024 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a specialty pharmaceutical company focused on delivering high-quality products to improve patient care, announced today the FDA has approved a supplemental New Drug Application (sNDA) for its Acetadote® (N-acetylcysteine for injection) product. Acetadote is an intravenous (IV) formulation of N-acetylcysteine (NAC) indicated to prevent or lessen liver injury after ingestion of potentially toxic quantities of acetaminophen1. Acetaminoph
– New Real World Study of 150,000 Patients Favors Caldolor over ketorolac – – DMD Program Receives FDA Orphan Drug & Rare Pediatric Disease Designations – NASHVILLE, Tenn., Nov. 7, 2024 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a specialty pharmaceutical company, today announced that its portfolio of FDA-approved brands delivered combined revenues of $9.1 million during the third quarter of 2024. The company ended the third quarter of 2024 with $77 million in total assets, $52 million in liabilities and $25 million of shareholders' equity.
SC 13G - CUMBERLAND PHARMACEUTICALS INC (0001087294) (Subject)
SC 13G - CUMBERLAND PHARMACEUTICALS INC (0001087294) (Subject)
SC 13G - CUMBERLAND PHARMACEUTICALS INC (0001087294) (Subject)
SC 13G/A - CUMBERLAND PHARMACEUTICALS INC (0001087294) (Subject)
SC 13G/A - CUMBERLAND PHARMACEUTICALS INC (0001087294) (Subject)
SC 13G - CUMBERLAND PHARMACEUTICALS INC (0001087294) (Subject)
SC 13G/A - CUMBERLAND PHARMACEUTICALS INC (0001087294) (Subject)
SC 13G/A - CUMBERLAND PHARMACEUTICALS INC (0001087294) (Subject)
SC 13G/A - CUMBERLAND PHARMACEUTICALS INC (0001087294) (Subject)